Ubiquitination, an important type of protein posttranslational modification (PTM), plays a
crucial role in controlling substrate degradation and subsequently mediates the “quantity” …

Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …

Abstract Background Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit
when administered in combination with bendamustine and rituximab and followed by …

Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Chronic inflammation and an immunosuppressive microenvironment promote prostate
cancer (PCa) progression and diminish the response to immune checkpoint blockade (ICB) …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …